Auteur M. R. LOFWALL

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Buprenorphine diversion and misuse in outpatient practice

M. R. LOFWALL ; J. MARTIN ; M. TIERNEY ; M. FATSEAS ; M. AURIACOMBE ; N. LINTZERIS | 2014
Dans Journal of Addiction Medicine (Vol.8, n°5, September-October 2014) Article : Périodique

This case is an amalgamation of several real patients in office-based treatment for prescription opioid dependence synthesized into a single theoretical case. The case illustrates the various ways in which medication diversion and misuse may be [...]

Plus d'info

Ajouter à la sélection

Characteristics of older opioid maintenance patients

M. R. LOFWALL ; R. K. BROONER ; G. E. BIGELOW ; K. KINDBOM ; E. C. STRAIN | 2005
Périodique

ENGLISH : The aging "baby boomer" population has higher rates of substance use than previous cohorts and is predicted to put increased demands on substance abuse treatment services; however; little is known about older illicit drug abusers. Th[...]

Plus d'info

Ajouter à la sélection

Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial

S. L. WALSH ; S. D. COMER ; M. R. LOFWALL ; B. VINCE ; N. LEVY-COOPERMAN ; D. KELSH ; M. A. COE ; J. D. JONES ; P. A. NUZZO ; F. TIBERG ; B. SHELDON ; S. KIM | 2017
Dans JAMA Psychiatry (Vol.74, n°9, September 2017) Article : Périodique

Importance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained r[...]

Plus d'info

Ajouter à la sélection

Efficacy of continuing medical education to reduce the risk of buprenorphine diversion

M. R. LOFWALL ; M. J. WUNSCH ; P. A. NUZZO ; S. L. WALSH | 2011
Dans Journal of Substance Abuse Treatment (Vol.41, n°3, October 2011) Article : Périodique

As office-based opioid dependence treatment (OBOT) has grown in the United States, postmarketing surveillance data reveal increased reports of buprenorphine misuse and diversion, it is important that doctors understand buprenorphine clinical pha[...]

Plus d'info

Ajouter à la sélection

A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world

M. R. LOFWALL ; S. L. WALSH | 2014
Dans Journal of Addiction Medicine (Vol.8, n°5, September-October 2014) Article : Périodique

Outpatient opioid addiction treatment with sublingual buprenorphine pharmacotherapy has rapidly expanded in the United States and abroad, and, with this increase in medication availability, there have been increasing concerns about its diversion[...]

Plus d'info

Ajouter à la sélection

The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers

L. S. MIDDLETON ; P. A. NUZZO ; M. R. LOFWALL ; D. E. MOODY ; S. L. WALSH | 2011
Dans Addiction (Vol.106, n°8, August 2011) Article : Périodique

AIMS Sublingual buprenorphine and buprenorphine/naloxone are efficacious opioid dependence pharmacotherapies, but there are reports of their diversion and misuse by the intranasal route. The study objectives were to characterize and compare thei[...]

Plus d'info

Ajouter à la sélection